TARRYTOWN, N.Y., May 24, 2012 /PRNewswire/ -- Bayer Radiology & Interventional will showcase new device technologies at the Annual Meeting of the Society of Nuclear Medicine (SNM) in Miami, June 9-13. The new technology includes enhancements to the Intego PET Infusion System, as well as developing platforms for controlled administration of molecular agents for SPECT and small animal imaging procedures.
In PET, the MEDRAD Intego System is a worldwide market leader and the only FDA cleared system for administration of 18F-FDG and 18F-NaF. Bayer has continued to innovate and evolve the Intego platform since its launch in 2008, including adding software features, expanding compatibility and indications, and significantly reducing the size of the device. At SNM, Bayer plans to demonstrate Certegra informatics solutions for Intego, including wireless integration to HIS/RIS/PACS systems which facilitate downloading the PET modality worklist as an infusion schedule and sending infusion results to PACS. This new capability will replace several manual processes, which in turn will streamline workflow and improve efficiency for PET imaging clinics.
Doug Descalzi, Bayer Sr. Director of Molecular Imaging Devices said, "Automated, controlled injection of molecular agents not only has safety and workflow benefits for staff, it can lead to improvements in patient care and help clinicians and scientists unlock the potential of molecular medicine."
In addition, in a scientific exhibition, the company will showcase developing technologies for controlled administration of low energy radiopharmaceuticals and for small animal molecular imaging. Both platforms demonstrate Bayer innovation and commitment to controlled administration technology.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conformthem to future events or developments.
SOURCE Bayer HealthCare